Clinical Trial Update: Randomized Trial of Gemcitabine/Cisplatin + PF-3512676 vs Gemcitabine/Cisplatin Alone in Patients With Advanced NSCLC [Phase 3]

View source ↗

Summary

Phase 3 randomized trial comparing gemcitabine/cisplatin with PF-3512676 vs without PF-3512676 in advanced non-small cell lung cancer was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• CISPLATIN (cisplatin)
• Gemzar (gemcitabine)
• PF-3512676

Snippet

Sponsor: Pfizer | Conditions: Carcinoma, Non-Small-Cell Lung | Phase 3 | Status: TERMINATED